Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PON1 | P27169 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1882248 | 0.98 | KDM4E (0.39) | KDM4EALDH1A1HTTHPGDPABPC1 | |
| SCHEMBL1886881 | 0.94 | KDM4E (0.38) | KDM4EALDH1A1HTTHPGDPABPC1 | |
| SCHEMBL12638811 | 0.94 | HTT (0.47) | HTT | |
| SCHEMBL12638802 | 0.94 | HTT (0.47) | HTT | |
| SCHEMBL12638809 | 0.94 | HTT (0.47) | HTT | |
| SCHEMBL23698379 | 0.94 | HTT (0.47) | HTT | |
| SCHEMBL23698566 | 0.94 | HTT (0.47) | HTT | |
| SCHEMBL12638806 | 0.94 | HTT (0.47) | HTT | |
| Bromide SCHEMBL3408562 | 0.94 | HTT (0.44) | HTT | |
| SCHEMBL12638810 | 0.94 | HTT (0.47) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291506-B2 | Method for producing amidate compound, and amidate compound | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2025-05-06 | — | — | US | disclosed |
| US-20220048864-A1 | METHOD FOR PRODUCING AMIDATE COMPOUND, AND AMIDATE COMPOUND | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2022-02-17 | — | — | US | disclosed |
| EP-3858817-A1 | METHOD FOR PRODUCING AMIDATE COMPOUND, AND AMIDATE COMPOUND | Koei Chemical Company, Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-112703184-A | Process for producing amide compound, and amide compound | 广荣化学株式会社 | 2021-04-23 | — | — | CN | disclosed |
| US-9260397-B2 | Salts comprising aryl-alkyl-substituted imidazolium and triazolium cations and the use thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2016-02-16 | — | — | US | disclosed |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291506-B2 | Method for producing amidate compound, and amidate compound | NAAA, NIT2, PAM | KDM4E 4058/4885ALDH1A1 4082/4885HTT 1900/4885 |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | RDX, HAX1, CHRM2 | KDM4E 4534/4885ALDH1A1 2684/4885HTT 1484/4885 |
| US-20220048864-A1 | METHOD FOR PRODUCING AMIDATE COMPOUND, AND AMIDATE COMPOUND | NAAA, NIT2, PAM | KDM4E 4058/4885ALDH1A1 4082/4885HTT 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.